Subject is currently receiving therapy with Rapamycin.

Subject is receiving any form of immunosuppression or has previously experienced immune dysfunction.

Subject is currently participating in or has participated within the last 30 days in a clinical trial involving an investigational drug.

Subject has a known hypersensitivity to either the vehicle or Rapamycin.

Subject is a pregnant or nursing female.

Subject has other dermatologic conditions that would preclude or prevent adequate assessment of changes to their facial angiofibromas.

Subject has had laser surgery, cryotherapy, or other dermatologic treatment to their facial angiofibromas within the previous 6 months.

Topical Rapamycin to Erase Angiofibromas in TSC